US
If visiting the DiaSorin Site from a region that doesn't coincide with your location, some products may not be available. This is due to regulatory requirements and restrictions.
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
Financial Data
06/11/23 - 15:44
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
Products
Immunodiagnostic
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
Financial Data
24/10/23 - 15:03
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
Other
27/07/23 - 14:27
Update 2023 Annual Calendar of Corporate Events (104.1 KB)
Other
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
Financial Data
17/07/23 - 7:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
Products
Immunodiagnostic
03/07/23 - 11:48
Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
Other
13/06/23 - 15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
Products
Immunodiagnostic
07/06/23 - 14:40
Communication of total amount of voting rights (7 June 2023) (141.14 KB)
Financial Disclosures
05/06/23 - 21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
Other
26/05/23 - 7:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
Acquisition / Partnership
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
Financial Data
28/04/23 - 12:52
Shareholders' Meeting 2023 (373.48 KB)
Other
27/03/23 - 15:52
Update 2023 Annual Calendar of Corporate Events (483.89 KB)
Financial Disclosures
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
Financial Data
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
Financial Data
17/03/23 - 22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
Products
Molecular
28/02/23 - 16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
Acquisition / Partnership
13/02/23 - 22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
Acquisition / Partnership
07/02/23 - 12:01
Update 2023 Annual Calendar of Corporate Events (288.3 KB)
Financial Disclosures